Work

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Year: 2018

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet HIV

DOI: 10.1016/s2352-3018(18)30091-2

Authors: Eric S Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K Rockstroh, Jean-Michel Molina, Ellen Koenig, Ya-Pei Liu, Joseph Custodio, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk

Institutions: The Lundquist Institute, Harbor–UCLA Medical Center, Orlando Immunology Center, Ruane Medical, Meridien Research, Howard Brown Health Center, University Hospital Bonn, Hôpital Saint-Louis, Gilead Sciences (United States)

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Gilead Sciences

OpenAlex ID: W2807931585

FWCI: 12.97

Cites: 25

Cited by: 178

Related to: 10